269 related articles for article (PubMed ID: 15628812)
1. Reduced severe hypoglycemia with insulin glargine in intensively treated adults with type 1 diabetes.
Garg SK; Paul JM; Karsten JI; Menditto L; Gottlieb PA
Diabetes Technol Ther; 2004 Oct; 6(5):589-95. PubMed ID: 15628812
[TBL] [Abstract][Full Text] [Related]
2. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.
Fulcher GR; Gilbert RE; Yue DK
Intern Med J; 2005 Sep; 35(9):536-42. PubMed ID: 16105155
[TBL] [Abstract][Full Text] [Related]
3. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus.
Mullins P; Sharplin P; Yki-Jarvinen H; Riddle MC; Haring HU
Clin Ther; 2007 Aug; 29(8):1607-19. PubMed ID: 17919543
[TBL] [Abstract][Full Text] [Related]
4. Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia.
Johansen OE; Vanberg PJ; Kilhovd BK; Jørgensen AP
Vasc Health Risk Manag; 2009; 5(1):121-8. PubMed ID: 19436668
[TBL] [Abstract][Full Text] [Related]
5. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin.
Rosenstock J; Schwartz SL; Clark CM; Park GD; Donley DW; Edwards MB
Diabetes Care; 2001 Apr; 24(4):631-6. PubMed ID: 11315821
[TBL] [Abstract][Full Text] [Related]
6. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin.
Porcellati F; Rossetti P; Pampanelli S; Fanelli CG; Torlone E; Scionti L; Perriello G; Bolli GB
Diabet Med; 2004 Nov; 21(11):1213-20. PubMed ID: 15498088
[TBL] [Abstract][Full Text] [Related]
7. Use of glargine in pregnant women with type 1 diabetes mellitus: a case-control study.
Imbergamo MP; Amato MC; Sciortino G; Gambina M; Accidenti M; Criscimanna A; Giordano C; Galluzzo A
Clin Ther; 2008 Aug; 30(8):1476-84. PubMed ID: 18803989
[TBL] [Abstract][Full Text] [Related]
8. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
Hemmingsen B; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
[TBL] [Abstract][Full Text] [Related]
9. Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study.
Sharplin P; Gordon J; Peters JR; Tetlow AP; Longman AJ; McEwan P
Cardiovasc Diabetol; 2009 Jan; 8():3. PubMed ID: 19152692
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy of insulin glargine after switching from NPH insulin as intensive replacement of basal insulin in Japanese diabetes mellitus. Comparison of efficacy between type 1 and type 2 diabetes (JUN-LAN Study 1.2).
Kanazawa Y; Igarashi Y; Komiya K; Sakurai Y; Shimizu T; Fujitani Y; Tanaka Y; Watada H; Kawamori R; Hirose T
Endocr J; 2007 Dec; 54(6):975-83. PubMed ID: 18000343
[TBL] [Abstract][Full Text] [Related]
11. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes.
Ratner RE; Hirsch IB; Neifing JL; Garg SK; Mecca TE; Wilson CA
Diabetes Care; 2000 May; 23(5):639-43. PubMed ID: 10834423
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland.
Brändle M; Azoulay M; Greiner RA
Int J Clin Pharmacol Ther; 2011 Mar; 49(3):217-30. PubMed ID: 21329624
[TBL] [Abstract][Full Text] [Related]
13. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.
Yki-Järvinen H; Dressler A; Ziemen M;
Diabetes Care; 2000 Aug; 23(8):1130-6. PubMed ID: 10937510
[TBL] [Abstract][Full Text] [Related]
14. Improved glycemic control with decreased hypoglycemia prevents long-term complications in type 2 diabetes patients: long-term simulation analysis using the "diabetes mellitus model".
Maxion-Bergemann S; Huppertz E; Jacobs LD; Müller E; Walleser S
Int J Clin Pharmacol Ther; 2005 Jun; 43(6):271-81. PubMed ID: 15968884
[TBL] [Abstract][Full Text] [Related]
15. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine.
Warren E; Weatherley-Jones E; Chilcott J; Beverley C
Health Technol Assess; 2004 Nov; 8(45):iii, 1-57. PubMed ID: 15525480
[TBL] [Abstract][Full Text] [Related]
16. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes.
Massi Benedetti M; Humburg E; Dressler A; Ziemen M
Horm Metab Res; 2003 Mar; 35(3):189-96. PubMed ID: 12734781
[TBL] [Abstract][Full Text] [Related]
17. Insulin glargine versus intermediate-acting insulin as the basal component of multiple daily injection regimens for adolescents with type 1 diabetes mellitus.
Chase HP; Arslanian S; White NH; Tamborlane WV
J Pediatr; 2008 Oct; 153(4):547-53. PubMed ID: 18589448
[TBL] [Abstract][Full Text] [Related]
18. Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients.
Pan CY; Sinnassamy P; Chung KD; Kim KW;
Diabetes Res Clin Pract; 2007 Apr; 76(1):111-8. PubMed ID: 17011662
[TBL] [Abstract][Full Text] [Related]
19. Glycaemic control and hypoglycaemia in children, adolescents and young adults with unstable type 1 diabetes mellitus treated with insulin glargine or intermediate-acting insulin.
Herwig J; Scholl-Schilling G; Böhles H
J Pediatr Endocrinol Metab; 2007 Apr; 20(4):517-25. PubMed ID: 17550216
[TBL] [Abstract][Full Text] [Related]
20. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine.
Garg SK; Gottlieb PA; Hisatomi ME; D'Souza A; Walker AJ; Izuora KE; Chase HP
Diabetes Res Clin Pract; 2004 Oct; 66(1):49-56. PubMed ID: 15364161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
